Holds one active US DMF for axitinib, filing since 2025. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for axitinib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 23 markets.
Holds one active US DMF for axitinib, filing since 2015. Its 2025 FDA inspection closed as NAI, and its GMP is recognised in 1 market.
Holds 2 active US DMFs for axitinib, filing since 2015. Its 2025 FDA inspection closed as VAI, and its GMP is recognised in 26 markets.
Holds one active US DMF for axitinib, filing since 2023. Its GMP is recognised in 14 markets.
Holds one active US DMF for axitinib, filing since 2023. Its 2024 FDA inspection closed as NAI.
Registered with SFDA (Saudi Arabia) for axitinib. Its GMP is recognised in 10 markets.
Registered with SFDA (Saudi Arabia) for axitinib.
The names are listed below. Ask Fred about the filings, inspection history and GMP certificates on record for each manufacturer.
Chat with Fred, your AI analystContract manufacturers make to order rather than holding their own filing for this molecule.
The order is set by active filings weighted by regulator, inspection outcomes and their recency, breadth of GMP recognition, and evidence of real exports, less any open risk flags. Every factor appears on the card it produced. Read the full method.
Ask Fred which manufacturers are on record for axitinib and what filings they hold.
Chat with Fred, your AI analyst